Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 7, 2020

Engaging in Recommended Amounts of Exercise Lowers the Risk of Seven Types of Cancer

Author(s):

Beth Fand Incollingo

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

According to a large new study, doing the recommended levels of leisure-time exercise lowers the risk of seven types of malignancies, including kidney and liver cancers.

The findings came from a pooled analysis of nine prospective studies that included more than 750,000 adults from the U.S., Europe and Australia who had no history of cancer and who self-reported their amounts of exercise.

Among 15 cancer types studied, adherence to recommended exercise amounts lowered the risk of liver cancer by 18% to 27%; of multiple myeloma by 14% to 19%; of non-Hodgkin lymphoma by 11% to 18% in women; of kidney cancer by 11% to 17%; of endometrial cancer by 10% to 18%; of colon cancer by 8% to 14% in men; and of breast cancer by 6% to 10%.

The exercise standards used in the study are recommended in the Physical Activity Guidelines for Americans released by the U.S. Department of Health and Human Services in 2018. The guidelines state that adults should engage in 2.5 to 5.0 hours per week of moderate-intensity activity or 1.25 to 2.5 hours per week of vigorous activity in order to avoid preventable chronic diseases.

The authors of the study defined moderate-intensity activities, such as brisk walking, as those that burn off three to six times as much energy per minute as sitting quietly, or three to six metabolic equivalents (METs). Vigorous-intensity activities were those that were aerobic and burned more than six METs.

Looking separately at moderate-intensity versus vigorous-intensity exercise, the authors found both to be beneficial in preventing colon, breast and kidney cancers but did not collect sufficient data to evaluate each exercise type independently in the other four kinds of cancer.

The researchers also looked at exercise amounts in excess of what was suggested in the guidelines. They determined that doing more than the suggested amount of activity further lowered the risk of colon, breast and endometrial cancers, but did not bring additional benefit in preventing kidney or liver cancers, myeloma or, in women only, non-Hodgkin lymphoma.

This indicates that there is “substantial variation in the underlying biologic mechanisms that link physical activity to different types of cancer,” the authors wrote. “Additional research is needed to better understand these differences.”

The authors embarked on the study to help determine the exact levels of physical activity needed to lower cancer risk. The U.S. Physical Activity Guidelines Advisory Committee had previously evaluated more than 40 reviews and meta-analyses that included multiple studies of this issue, but without determining conclusive answers.

“Our findings provide robust quantitative evidence that supports the new U.S. Physical Activity Guidelines for cancer prevention as well as recommendations that have been promoted by the American Cancer Society, World Cancer Research Fund International, the International Agency for Research on Cancer and the American College of Sports Medicine,” the study’s authors wrote.

They added that "These findings provide direct quantitative support for the levels of activity recommended for cancer prevention and provide actionable evidence for ongoing and future cancer prevention efforts."

Alpa Patel, senior scientific director of epidemiology research at the American Cancer Society, noted that, while "physical activity guidelines have largely been based on their impact on chronic diseases like cardiovascular disease and diabetes,” the study’s findings “provide strong support that these recommended levels are important to cancer prevention, as well."

The analysis was conducted by researchers at the National Cancer Institute, the American Cancer Society, the Harvard T.H. Chan School of Public Health and other institutions. Results were published in the Journal of Clinical Oncology in December 2019.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Image of man.
Image of man with black hair.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
Related Content
Advertisement
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine in advanced kidney cancer: © stock.adobe.com.
June 6th 2025

Personalized Vaccine Elicits Responses in Patients With Kidney Cancer

Alex Biese
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of kidneys.
May 27th 2025

Dose Escalation Complete in Kidney Cancer Trial of HC-7366 Plus Welireg

Ryan Scott
A phase 1b study of HC-7366 plus Welireg for advanced clear cell renal cell carcinoma has completed the dose escalation portion of the clinical trial.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Living with stage 4 kidney cancer has taught me to embrace the present: © stock.adobe.com.
May 12th 2025

Finding Strength and Joy During My Stage 4 Kidney Cancer Experience

Chuck Stravin
Living with stage 4 kidney cancer has taught me to embrace the present, cherish connection and find gratitude each day in unexpected places.
Carmela Cuccurullo, AGPCNP-BC, OCN
May 9th 2025

Unmatched Energy, Every Single Day

Carmela Cuccurullo, AGPCNP-BC, OCN
For the past 2 years, I have worked alongside Carmela Cuccurullo, NP.
Related Content
Advertisement
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine in advanced kidney cancer: © stock.adobe.com.
June 6th 2025

Personalized Vaccine Elicits Responses in Patients With Kidney Cancer

Alex Biese
CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced kidney cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of kidneys.
May 27th 2025

Dose Escalation Complete in Kidney Cancer Trial of HC-7366 Plus Welireg

Ryan Scott
A phase 1b study of HC-7366 plus Welireg for advanced clear cell renal cell carcinoma has completed the dose escalation portion of the clinical trial.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Living with stage 4 kidney cancer has taught me to embrace the present: © stock.adobe.com.
May 12th 2025

Finding Strength and Joy During My Stage 4 Kidney Cancer Experience

Chuck Stravin
Living with stage 4 kidney cancer has taught me to embrace the present, cherish connection and find gratitude each day in unexpected places.
Carmela Cuccurullo, AGPCNP-BC, OCN
May 9th 2025

Unmatched Energy, Every Single Day

Carmela Cuccurullo, AGPCNP-BC, OCN
For the past 2 years, I have worked alongside Carmela Cuccurullo, NP.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.